Laura Malahias has over 10 years of experience in clinical development including work at the study site level, small and large CRO and as a sponsor. Currently she is serving as Director of Clinical Operations at TARGET PharmaSolutions.
Prior to joining TARGET, Laura was the Clinical Research Manager at Aerial BioPharma, a successful drug development company where she helped manage its lead product, ADX-N05, which was subsequently out-licensed to Jazz Pharmaceuticals in 2014. Prior to her work at Aerial BioPharma, Laura worked with the same team at Neuronex Pharmaceuticals, a specialty drug development company sold to Acorda Therapeutics and Addrenex Pharmaceuticals, a pharmaceutical development company acquired by Shionogi Pharma.
Laura’s broad experience includes trial management, monitoring, medical writing, and data management.